Throughout 2025, Clearmind achieved critical milestones in its FDA-approved Phase I/IIa clinical trial for CMND-100, a proprietary non-hallucinogenic MEAI-based oral compound designed to address AUD—a ...

Shares of Clearmind Medicine Inc. (NASDAQ:CMND) are falling Friday after the clinical-stage biotech company shared a key update about its stock listing. What To Know: Clearmind said it received a ...

The company said, “Throughout 2025, Clearmind achieved critical milestones in its FDA-approved Phase I/IIa clinical trial for CMND-100, a ...

As of 2:45:26 PM EST. Market Open.

Clearmind Medicine (CMND) announced another key milestone in its Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder: the first participant has been enrolled and dosed with CMND-100, ...

Vancouver, Canada, March 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and ...

Clearmind has 28 granted patents across 18 patent families, with patents granted in major jurisdictions. Clearmind shares are trading higher Friday after the company announced advancement in its ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Clearmind Medicine's net income for the latest quarter was -1.31. How does Clearmind Medicine's debt to equity ratio compare to industry standards? Clearmind Medicine's total debt-to-equity ratio is 2 ...